J. Goldman & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

J. Goldman & Co’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,000	Closed	-$4.47M	–	947
2026 Q1	$4.47M	Buy	+10,000	New	+$4.66M	0.13%	199
2025 Q1	–	Sell	-6,000	Closed	-$2.42M	–	658
2024 Q4	$2.42M	Buy	+6,000	New	+$2.78M	0.06%	262
2024 Q1	–	Sell	-8,200	Closed	-$3.34M	–	527
2023 Q4	$3.34M	Buy	+8,200	New	+$3.03M	0.14%	152
2023 Q1	–	Sell	-55,000	Closed	-$15.9M	–	492
2022 Q4	$15.9M	Buy	+55,000	New	+$16.8M	0.78%	35
2022 Q1	–	Sell	-7,500	Closed	-$1.65M	–	454
2021 Q4	$1.65M	Buy	+7,500	New	+$1.46M	0.09%	221
2021 Q2	–	Sell	-33,700	Closed	-$7.24M	–	526
2021 Q1	$7.24M	Buy	+33,700	New	+$7.4M	0.23%	112

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

J. Goldman & Co's VRTX Position: Q2 2026 in Review

J. Goldman & Co opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 12,311 shares worth $6.12M. The stake represents 0.16% of the portfolio and ranks #176 among its holdings. This is a return to the name: J. Goldman & Co previously reported a position in VRTX as recently as Q2 2025.

J. Goldman & Co first reported a position in VRTX in Q2 2017 and has held it in 9 quarters since. The position peaked at $8.71M in Q4 2022. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

J. Goldman & Co held 12,311 shares of Vertex Pharmaceuticals worth $6.12M as of Q2 2026.
Vertex Pharmaceuticals was a new J. Goldman & Co position in Q2 2026.
Vertex Pharmaceuticals made up 0.16% of J. Goldman & Co's portfolio in Q2 2026, its #176 holding.
J. Goldman & Co first reported a position in Vertex Pharmaceuticals in Q2 2017 and has held it in 9 quarters since.
J. Goldman & Co's Vertex Pharmaceuticals position peaked at $8.71M in Q4 2022.
1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.